CareDx Joins Forces with MOTTEP, The National Minority Organ Tissue Transplant Education Program, to Host “Heart Health” Webinar for Transplant Patients
February 07, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
CareDx To Participate In Upcoming Conferences
February 03, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
CareDx Joins Forces with MOTTEP to Increase Organ Donations for Minority Transplant Patients and Support High-Risk, Underserved Communities
January 20, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
Landmark ADMIRAL Study Publication with CareDx’s AlloSure Kidney is the First Long-Term Multicenter Prospective Clinical Validation for Routine Organ Transplant Surveillance
January 12, 2022 07:00 ET
|
CareDx, Inc.
ADMIRAL Study Shows AlloSure Detects Clinical and Subclinical ABMR and TCMR, and Predicts Long-Term Outcomes for Kidney Transplant Patients AlloSure Showed 62% Improvement Over Standard of Care Serum...
CareDx Partners with Multiple Biotechnology Companies to Use AlloCell in CAR T-Cell Therapy Clinical Studies
January 11, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021
January 10, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) -- The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
NIH Study Shows Using CareDx’s AlloSure Lung for Transplant Surveillance is More Effective than Diagnostic Bronchoscopy at Identifying Rejection
January 07, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
CareDx Successfully Completes CLIA Validation of AlloMap Kidney in Preparation for Commercial Launch
January 06, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
CareDx Expands Its Medication Adherence Services with the Acquisition of The Transplant Pharmacy
January 05, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...
CareDx Partners with ISHLT in a Transplant Innovation Research Grant to Improve Outcomes for Heart and Lung Transplant Patients
January 04, 2022 07:00 ET
|
CareDx, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically...